The outcomes revealed that mTT NPs (loaded with tumor antigens from mixture of 26 allogeneic tumor tissues of patients with NSCLC) and mTC NPs (loaded with tumor antigens from mixture of 7 lung cancer cell lines) activated more CD8+IFNγ+ T cells compared to other NPs loaded with tumor antigens from single tumor tissue or single cell line or multiple neoantigen peptides (Figure 4g; Figure S8e, Supporting Information). The gene discussed is CD8A; the disease is lung cancer.